Ignite Creation Date:
2024-05-06 @ 7:04 AM
Last Modification Date:
2024-10-26 @ 11:44 AM
Study NCT ID:
NCT02463409
Status:
COMPLETED
Last Update Posted:
2017-06-26
First Post:
2015-05-20
Brief Title:
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a Albright Hereditary Osteodystrophy
Sponsor:
Vanderbilt University Medical Center
Organization:
Vanderbilt University Medical Center
Study Overview
Official Title:
Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test an investigational drug theophylline in children with pseudohypoparathyroidism type 1a PHP1a This study involves a 3 day visit to the Vanderbilt Clinical Research Center
Detailed Description:
Study measures will be done at baseline and during a 24h infusion of IV theophylline Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity Measures include laboratory values response to PTH infusion and resting energy expenditure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None